<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">xPD9vTjffyXK6JngS7bQ7zJ</article-id>
      <article-id pub-id-type="other">00005</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000600005</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200605</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000600005</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Preval&#234;ncia de Chlamydia Pneumoniae e Mycoplasma Pneumoniae em diferentes formas da doen&#231;a coronariana</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Maia</surname>
            <given-names>Irineu Luiz</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nicolau</surname>
            <given-names>Jos&#233; Carlos</given-names>
          </name>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Machado</surname>
            <given-names>Maur&#237;cio de Nassau</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maia</surname>
            <given-names>L&#237;lia Nigro</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takakura</surname>
            <given-names>Isabela Thomaz</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rocha</surname>
            <given-names>Paulo Ricardo de Fernando</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cordeiro</surname>
            <given-names>Jos&#233; Ant&#244;nio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ramires</surname>
            <given-names>Jos&#233; Ant&#244;nio Franchini</given-names>
          </name>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Jos&#233; do Rio Preto</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <institution content-type="orgname">Faculdade de Medicina de S&#227;o Jos&#233; do Rio Preto</institution>
        <country country="BR">Brasil</country>
      </aff>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="city">S&#227;o Jos&#233; do Rio Preto</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Instituto do Cora&#231;&#227;o</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">S&#227;o Jos&#233; do Rio Preto</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <institution content-type="orgname">Hospital de Base de S&#227;o Jos&#233; do Rio Preto</institution>
        <country country="BR">Brasil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>06</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>6</issue>
      <fpage>439</fpage>
      <lpage>445</lpage>
      <history>
        <date date-type="accepted">
          <day>30</day>
          <month>05</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>06</day>
          <month>05</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>16</day>
          <month>11</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: V&#225;rios agentes infecciosos foram investigados desde que se demonstrou a associa&#231;&#227;o entre infec&#231;&#227;o e aterosclerose, por&#233;m os resultados desses estudos s&#227;o conflitantes. OBJETIVO: Testar a associa&#231;&#227;o entre t&#237;tulos s&#233;ricos de anticorpos anti-Chlamydia e anti-Mycoplasma em diferentes formas de s&#237;ndromes coronarianas agudas (SCA). M&#201;TODOS: Cento e vinte e seis pacientes foram divididos em quatro grupos: SCA com eleva&#231;&#227;o do segmento ST (32 pacientes), SCA sem eleva&#231;&#227;o do segmento ST (30 pacientes), doen&#231;a arterial coronariana cr&#244;nica (30 pacientes) e doadores de sangue sem doen&#231;a coronariana conhecida (34 pacientes - grupo-controle). Nos primeiros dois grupos, amostras de soro foram coletadas na admiss&#227;o (primeiras 24 horas de hospitaliza&#231;&#227;o) e ap&#243;s 6 meses de seguimento. Nos outros dois grupos, colheu-se apenas uma amostra basal. Em todas as amostras, anticorpos IgG anti-Chlamydia e anti-Mycoplasma foram dosados por imunofluoresc&#234;ncia indireta. RESULTADOS: Diferen&#231;as significativas foram observadas entre a medida basal e ap&#243;s 6 meses de seguimento nos pacientes com infarto do mioc&#225;rdio com eleva&#231;&#227;o do segmento ST, tanto para Chlamydia (650&#177;115,7 vs. 307&#177;47,5, p = 0,0001) quanto para Mycoplasma (36,5&#177;5,0 vs. 21,5&#177;3,5, p = 0,0004). Os grupos com SCA tiveram n&#237;veis s&#233;ricos de anticorpos anti-Chlamydia e anti-Mycoplasma mais altos na dosagem basal, em rela&#231;&#227;o aos pacientes com doen&#231;a arterial coronariana cr&#244;nica e grupo-controle, mas as diferen&#231;as obtidas n&#227;o tiveram signific&#226;ncia estat&#237;stica. CONCLUS&#195;O: O presente estudo mostrou associa&#231;&#227;o entre os t&#237;tulos de anticorpos anti-Chlamydia e anti-Mycoplasma na fase aguda dos pacientes com angina inst&#225;vel ou infarto do mioc&#225;rdio.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Chlamydophila pneumoniae</kwd>
        <kwd>mycoplasma pneumoniae</kwd>
        <kwd>aterosclerose</kwd>
        <kwd>doen&#231;a da art&#233;ria coronariana</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>20</day>
        <month>07</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> CORONARIOPATIA AGUDA</p>
    <p>Preval&#234;ncia de <italic><bold>Chlamydia Pneumoniae</bold></italic> e <italic><bold>Mycoplasma Pneumoniae</bold></italic> em diferentes formas da doen&#231;a coronariana</p>
    <p>
      <bold>Irineu Luiz Maia<sup>I, II</sup>; Jos&#233; Carlos Nicolau<sup>III</sup>; Maur&#237;cio de Nassau Machado<sup>I, II</sup>; L&#237;lia Nigro Maia<sup>I, II</sup>; Isabela Thomaz Takakura<sup>II</sup>; Paulo Ricardo de Fernando Rocha<sup>II</sup>; Jos&#233; Ant&#244;nio Cordeiro<sup>I</sup>; Jos&#233; Ant&#244;nio Franchini Ramires<sup>III</sup></bold>
    </p>
    <p><sup>I</sup>Faculdade de Medicina de S&#227;o Jos&#233; do Rio Preto (Famerp), S&#227;o Jos&#233; do Rio Preto, SP; S&#227;o Paulo, SP - Brasil </p>
    <p><sup>II</sup>Hospital de Base de S&#227;o Jos&#233; do Rio Preto, S&#227;o Jos&#233; do Rio Preto, SP; S&#227;o Paulo, SP - Brasil </p>
    <p><sup>III</sup>Instituto do Cora&#231;&#227;o - Faculdade de Medicina da Universidade de S&#227;o Paulo (InCor &#150; USP), S&#227;o Jos&#233; do Rio Preto, SP; S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO: </bold>V&#225;rios agentes infecciosos foram investigados desde que se demonstrou a associa&#231;&#227;o entre infec&#231;&#227;o e aterosclerose, por&#233;m os resultados desses estudos s&#227;o conflitantes. </p>
    <p><bold>OBJETIVO: </bold>Testar a associa&#231;&#227;o entre t&#237;tulos s&#233;ricos de anticorpos anti-<italic>Chlamydia</italic> e anti-<italic>Mycoplasma</italic> em diferentes formas de s&#237;ndromes coronarianas agudas (SCA). </p>
    <p><bold>M&#201;TODOS: </bold>Cento e vinte e seis pacientes foram divididos em quatro grupos: SCA com eleva&#231;&#227;o do segmento ST (32 pacientes), SCA sem eleva&#231;&#227;o do segmento ST (30 pacientes), doen&#231;a arterial coronariana cr&#244;nica (30 pacientes) e doadores de sangue sem doen&#231;a coronariana conhecida (34 pacientes &#150; grupo-controle). Nos primeiros dois grupos, amostras de soro foram coletadas na admiss&#227;o (primeiras 24 horas de hospitaliza&#231;&#227;o) e ap&#243;s 6 meses de seguimento. Nos outros dois grupos, colheu-se apenas uma amostra basal. Em todas as amostras, anticorpos IgG anti-<italic>Chlamydia</italic> e anti-<italic>Mycoplasma</italic> foram dosados por imunofluoresc&#234;ncia indireta. </p>
    <p><bold>RESULTADOS:</bold> Diferen&#231;as significativas foram observadas entre a medida basal e ap&#243;s 6 meses de seguimento nos pacientes com infarto do mioc&#225;rdio com eleva&#231;&#227;o do segmento ST, tanto para <italic>Chlamydia</italic> (650&#177;115,7 vs. 307&#177;47,5, p = 0,0001) quanto para <italic>Mycoplasma</italic> (36,5&#177;5,0 vs. 21,5&#177;3,5, p = 0,0004). Os grupos com SCA tiveram n&#237;veis s&#233;ricos de anticorpos anti-<italic>Chlamydia</italic> e anti-<italic>Mycoplasma</italic> mais altos na dosagem basal, em rela&#231;&#227;o aos pacientes com doen&#231;a arterial coronariana cr&#244;nica e grupo-controle, mas as diferen&#231;as obtidas n&#227;o tiveram signific&#226;ncia estat&#237;stica. </p>
    <p><bold>CONCLUS&#195;O:</bold> O presente estudo mostrou associa&#231;&#227;o entre os t&#237;tulos de anticorpos anti-<italic>Chlamydia</italic> e anti-<italic>Mycoplasma</italic> na fase aguda dos pacientes com angina inst&#225;vel ou infarto do mioc&#225;rdio. </p>
    <p><bold>Palavras-chave: </bold><italic>Chlamydophila pneumoniae</italic>, <italic>mycoplasma pneumoniae</italic>, aterosclerose, doen&#231;a da art&#233;ria coronariana.</p>
    <p>
      <bold>Introdu&#231;&#227;o </bold>
    </p>
    <p>Desde 1978, quando se demonstrou pela primeira vez a associa&#231;&#227;o entre infec&#231;&#227;o e aterosclerose<sup>1</sup>, v&#225;rios agentes infecciosos foram investigados<sup>2</sup>. Dentre esses, &#233; a <italic>Chlamydia pneumoniae </italic>(Cp) que apresenta maiores evid&#234;ncias quanto &#224; sua participa&#231;&#227;o na doen&#231;a ateroscler&#243;tica est&#225;vel, no infarto agudo do mioc&#225;rdio (IAM) e no acidente vascular cerebral (AVC)<sup>3-7</sup>.</p>
    <p>Entretanto, os resultados contradit&#243;rios dos estudos que testaram os efeitos de antibi&#243;ticos anti-Cp na redu&#231;&#227;o de eventos cardiovasculares colocaram em d&#250;vida a participa&#231;&#227;o da infec&#231;&#227;o e, mais especificamente, da Cp na doen&#231;a ateroscler&#243;tica.</p>
    <p>Em 2000, Higuchi e cols.<sup>8,9</sup>, em estudo de pe&#231;as de necropsia, al&#233;m de confirmarem uma alta quantidade de c&#233;lulas infectadas pela Cp em placas ateroscler&#243;ticas rotas, demonstraram de forma pioneira a presen&#231;a de um outro agente infeccioso no local, posteriormente identificado como <italic>Mycoplasma pneumoniae </italic>(Mp)<sup>8,9</sup>. </p>
    <p>Esse agente infeccioso comporta-se como superant&#237;geno e necessita do colesterol para sobreviver, uma vez que sua membrana &#233; constitu&#237;da dessa subst&#226;ncia<sup>10</sup>. Do ponto de vista fisiopatol&#243;gico, uma hip&#243;tese atraente seria a de que o Mp funcionaria como um "gatilho" para a ativa&#231;&#227;o da Cp, promovendo assim a instabilidade da placa ateroscler&#243;tica coronariana. </p>
    <p>Esse estudo-piloto foi planejado para avaliar, por meio de investiga&#231;&#227;o sorol&#243;gica, o papel desses dois agentes bacterianos no desencadeamento de eventos isqu&#234;micos coronarianos agudos.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>
      <bold>Desenho do estudo</bold>
    </p>
    <p>Este estudo foi aprovado pelo Comit&#234; de &#201;tica em Pesquisa local, e todos os pacientes assinaram o Termo de Consentimento Livre e Esclarecido.</p>
    <p>No per&#237;odo de mar&#231;o de 2002 a novembro de 2004, foram inclu&#237;dos de forma prospectiva 138 pacientes, sendo:</p>
    <p>a) 34 pacientes portadores de IAM com supradesnivelamento do segmento ST (idade m&#233;dia de 55,1&#177;1,7 anos, sendo 73,5% do sexo masculino);</p>
    <p>b) 40 pacientes portadores de angina inst&#225;vel ou IAM sem supradesnivelamento do segmento ST (idade m&#233;dia de 60,1&#177;2,1 anos, sendo 52,5% do sexo masculino); </p>
    <p>c) 30 pacientes portadores de aterosclerose cr&#244;nica, assintom&#225;ticos ou portadores de angina est&#225;vel (idade m&#233;dia de 65,9&#177;2,0 anos, sendo 63,3% do sexo masculino);</p>
    <p>d) 34 indiv&#237;duos sem doen&#231;a coronariana conhecida, doadores de sangue (idade m&#233;dia de 42,5&#177;1,2 anos, sendo 64,7% do sexo masculino).</p>
    <p>
      <bold>Objetivo prim&#225;rio</bold>
    </p>
    <p>O objetivo principal do estudo foi testar a associa&#231;&#227;o entre t&#237;tulos sorol&#243;gicos de anticorpos anti-<italic>Chlamydia pneumoniae </italic>e anti-<italic>Mycoplasma pneumoniae </italic>(anti-Cp e anti-Mp) e s&#237;ndromes isqu&#234;micas mioc&#225;rdicas inst&#225;veis (SIMI).</p>
    <p>
      <bold>Crit&#233;rios de inclus&#227;o</bold>
    </p>
    <p>Foram inclu&#237;dos pacientes de ambos os sexos com idade acima de 18 anos, ap&#243;s terem assinado o termo de consentimento informado. Os diferentes grupos foram assim definidos:</p>
    <p>
      <bold>a) SIMI com supradesnivelamento do segmento ST</bold>
    </p>
    <p>Pacientes que apresentavam dor com caracter&#237;sticas anginosas <underline>&lt;</underline> 24 horas de evolu&#231;&#227;o, que preencheram pelo menos dois dos seguintes crit&#233;rios de IAM: </p>
    <p><italic>&#8226; Cl&#237;nicos</italic>: dor retroesternal de forte intensidade e car&#225;ter opressivo, dura&#231;&#227;o superior a 20 minutos, que n&#227;o cedeu com o uso de nitratos.</p>
    <p><italic>&#8226; Eletrocardiogr&#225;ficos</italic>: supradesnivelamento do segmento ST <underline>&gt;</underline> 1 mm em pelo menos duas deriva&#231;&#245;es perif&#233;ricas e/ou supradesnivelamento do segmento ST <underline>&gt;</underline> 2 mm em pelo menos duas deriva&#231;&#245;es consecutivas precordiais e/ou presen&#231;a de bloqueio de ramo esquerdo.</p>
    <p><italic>&#8226; Marcadores de necrose mioc&#225;rdica</italic>: eleva&#231;&#227;o de pelo menos duas vezes em rela&#231;&#227;o aos valores normais da CKMB atividade (normal at&#233; 25 U/l) e/ou troponina T (normal at&#233; 0,010 ng/ml).</p>
    <p>
      <bold>b) SIMI sem supradesnivelamento do segmento ST</bold>
    </p>
    <p>Pacientes que apresentavam dor com caracter&#237;sticas anginosas <underline>&lt;</underline> 24 horas de evolu&#231;&#227;o, com (IAM sem supradesnivelamento do segmento ST) ou sem (angina inst&#225;vel) eleva&#231;&#227;o dos biomarcadores de necrose mioc&#225;rdica (CKMB e/ou troponina T). Foram selecionados nesse grupo apenas pacientes de alto risco, de acordo com a classifica&#231;&#227;o da Sociedade Brasileira de Cardiologia (SBC) <sup>11</sup>.</p>
    <p>&#149; Idade &gt; 75 anos.</p>
    <p>&#149; Dor progressiva, sintomas nas &#250;ltimas 48 horas.</p>
    <p>&#149; Dor prolongada (&gt; 20 min), em repouso.</p>
    <p>&#149; Edema pulmonar, piora ou surgimento de sopro de regurgita&#231;&#227;o mitral, B3, hipotens&#227;o, bradicardia e taquicardia.</p>
    <p>&#149; Infradesnivelamento do segmento ST <underline>&gt;</underline> 0,5 mm (associado ou n&#227;o com angina), altera&#231;&#227;o din&#226;mica do ST, bloqueio completo de ramo, novo ou presumidamente novo. Taquicardia ventricular sustentada. </p>
    <p>&#149; Marcadores de isquemia acentuadamente elevados (&gt; percentil 99).</p>
    <p>
      <bold>c) Grupo aterosclerose cr&#244;nica</bold>
    </p>
    <p>Pacientes com doen&#231;a ateroscler&#243;tica coronariana cr&#244;nica assintom&#225;tica ou com angina est&#225;vel. A presen&#231;a da doen&#231;a foi definida pelos seguintes crit&#233;rios:</p>
    <p><italic>&#8226; </italic>IAM pr&#233;vio; e/<italic>ou</italic></p>
    <p><italic>&#8226; </italic>Revasculariza&#231;&#227;o cir&#250;rgica do mioc&#225;rdio pr&#233;via; e/<italic>ou</italic></p>
    <p><italic>&#8226; </italic>Interven&#231;&#227;o coronariana percut&#226;nea pr&#233;via; e/<italic>ou</italic></p>
    <p><italic>&#8226; </italic>Cineangiocoronariografia pr&#233;via demonstrando les&#245;es obstrutivas de art&#233;rias coron&#225;rias.</p>
    <p>
      <bold>d) Grupo-controle </bold>
    </p>
    <p>Indiv&#237;duos selecionados aleatoriamente a partir dos doadores de sangue do Hospital de Base e que negavam a presen&#231;a de qualquer doen&#231;a ateroscler&#243;tica conhecida.</p>
    <p>
      <bold>Crit&#233;rios de exclus&#227;o</bold>
    </p>
    <p>Foram exclu&#237;dos os pacientes que apresentaram pelo menos um dos seguintes crit&#233;rios:</p>
    <p><italic>&#8226; </italic>Dificuldade de compreens&#227;o do consentimento informado;</p>
    <p><italic>&#8226; </italic>Recusa em assinar o consentimento informado;</p>
    <p><italic>&#8226; </italic>Impossibilidade de retornar para o seguimento do estudo;</p>
    <p><italic>&#8226; </italic>Idade inferior a 18 anos;</p>
    <p><italic>&#8226; </italic>Tempo de evolu&#231;&#227;o &gt; 24 horas;</p>
    <p><italic>&#8226; </italic>Infec&#231;&#227;o ativa;</p>
    <p><italic>&#8226; </italic>Uso de antimicrobianos nos &#250;ltimos 30 dias;</p>
    <p><italic>&#8226; </italic>Doen&#231;as terminais.</p>
    <p>
      <bold>Metodologia da coleta sangu&#237;nea</bold>
    </p>
    <p>Nos grupos portadores de SIMI com e sem supradesnivelamento ST, amostras sangu&#237;neas foram colhidas em duas ocasi&#245;es, a primeira durante o evento agudo e a segunda 6 meses ap&#243;s. Nos outros dois grupos (aterosclerose cr&#244;nica e controle), tais amostras foram coletadas apenas uma vez. Como a meia-vida dos anticorpos da classe IgG &#233; de 30 dias, a coleta ap&#243;s 6 meses do evento agudo visou refletir os valores basais de uma pessoa infectada cronicamente, tanto pela Cp como pelo Mp.</p>
    <p>Em todas as amostras, foram dosados os t&#237;tulos de anticorpos anti-Cp e anti-Mp da classe IgG com os resultados expressos pelo maior valor da dilui&#231;&#227;o em que a rea&#231;&#227;o foi positiva.</p>
    <p>
      <bold>Exames laboratoriais</bold>
    </p>
    <p>Os exames sorol&#243;gicos foram realizados por um &#250;nico e experiente examinador, de forma cega e usando a t&#233;cnica de imunofluoresc&#234;ncia indireta<sup>12</sup>. </p>
    <p>
      <bold>An&#225;lise estat&#237;stica </bold>
    </p>
    <p>Os dados categ&#243;ricos s&#227;o apresentados em n&#250;meros absolutos e percentuais, e as vari&#225;veis cont&#237;nuas em m&#233;dia &#177; erro padr&#227;o (EP) para maior clareza. As vari&#225;veis cont&#237;nuas n&#227;o tiveram distribui&#231;&#227;o gaussiana e foram avaliadas por testes n&#227;o-param&#233;tricos (Kruskal-Wallis e Wilcoxon)<sup>13</sup>. Gr&#225;ficos tipo <italic>Box Plot</italic> s&#227;o apresentados em mediana e interquartis. Valores p &lt; 0,05 foram considerados estatisticamente significativos (bicaudais). O <italic>software</italic> utilizado para a an&#225;lise estat&#237;stica foi o StatsDirect Statistics Software v. 2.6.5.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>O tamanho da amostra recomendado foi de 30 pacientes por grupo, totalizando 120 pacientes. </p>
    <p>No decorrer do estudo, oito pacientes faleceram, sendo dois do grupo SIMI com supra ST e seis do grupo SIMI sem supradesnivelamento ST. Quatro pacientes do grupo SIMI sem supradesnivelamento ST n&#227;o compareceram aos retornos pr&#233;-agendados e ap&#243;s v&#225;rias tentativas malsucedidas de contato, foram considerados como perda de seguimento, e, portanto, nesses casos, n&#227;o foi poss&#237;vel colher a segunda sorologia. </p>
    <p>Essas perdas foram repostas, tendo sido inclu&#237;dos no total 138 pacientes: 34 no grupo SIMI com supradesnivelamento ST; 40 pacientes no grupo SIMI sem supradesnivelamento ST; 30 pacientes no grupo aterosclerose cr&#244;nica e 34 indiv&#237;duos no grupo-controle. Apenas os pacientes que realizaram todas as sorologias planejadas para o seu grupo foram inclu&#237;dos em todas as an&#225;lises realizadas no estudo. </p>
    <p>
      <bold>Caracter&#237;sticas cl&#237;nicas dos pacientes </bold>
    </p>
    <p>Na <xref ref-type="table" rid="tab01">tabela 1</xref>, est&#227;o relacionadas as caracter&#237;sticas cl&#237;nicas dos 126 pacientes que realizaram todas as sorologias planejadas. </p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gt01.jpg"/></table-wrap>
    <p>Vale destacar a alta preval&#234;ncia de fatores de risco encontrados no grupo aterosclerose cr&#244;nica (83,3% eram hipertensos, 53,3% tabagistas e 90% dislipid&#234;micos).</p>
    <p>
      <bold>Compara&#231;&#227;o entre as sorologias obtidas na admiss&#227;o e 6 meses ap&#243;s interna&#231;&#227;o nos grupos com e sem supradesnivelamento do segmento ST</bold>
    </p>
    <p>Nos <xref ref-type="fig" rid="grf01">gr&#225;ficos 1</xref> e <xref ref-type="fig" rid="grf02">2</xref>, demonstram-se os valores sorol&#243;gicos colhidos na fase aguda do evento coronariano e 6 meses ap&#243;s, nos grupos com e sem supradesnivelamento do segmento ST, sendo essa an&#225;lise o objetivo principal do estudo. </p>
    <fig id="grf01">
      <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gf01.jpg"/></fig>
    <fig id="grf02">
      <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gf02.jpg"/></fig>
    <p>Os pacientes portadores de SIMI com supradesnivelamento apresentaram significativa redu&#231;&#227;o dos t&#237;tulos sorol&#243;gicos nas coletas realizadas 6 meses ap&#243;s a interna&#231;&#227;o, tanto em rela&#231;&#227;o &#224; Cp (p = 0,0001) quanto em rela&#231;&#227;o ao Mp (p = 0,0004). </p>
    <p>N&#227;o foi observado o mesmo comportamento sorol&#243;gico no grupo sem supradesnivelamento do segmento ST, tanto para a Cp como para o Mp (p = 0,27 e 0,99, respectivamente). </p>
    <p>
      <bold>Compara&#231;&#227;o entre os valores sorol&#243;gicos realizados no in&#237;cio do estudo </bold>
    </p>
    <p>Os <xref ref-type="fig" rid="grf03">gr&#225;ficos 3</xref> e <xref ref-type="fig" rid="grf04">4</xref> comparam as diferen&#231;as sorol&#243;gicas entre os diferentes grupos analisados (primeira amostra sorol&#243;gica). </p>
    <fig id="grf03">
      <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gf03.jpg"/></fig>
    <fig id="grf04">
      <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gf04.jpg"/></fig>
    <p>Notam-se, nos grupos que apresentaram isquemia mioc&#225;rdica aguda (SIMI com e sem supradesnivelamento ST), valores sorol&#243;gicos mais elevados comparados aos grupos que n&#227;o tiveram evento agudo (aterosclerose cr&#244;nica e controle), tanto em rela&#231;&#227;o &#224; Cp quanto ao Mp, embora essas diferen&#231;as n&#227;o tenham atingido signific&#226;ncia estat&#237;stica. </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>O presente estudo foi motivado pela necessidade de se avaliar, clinicamente, a presen&#231;a concomitante do <italic>Mycoplasma pneumoniae </italic>e da <italic>Chlamydia pneumoniae</italic> em les&#245;es ateromatosas coronarianas, descrita previamente por Higuchi e cols<sup>9</sup> em achados de necropsia.</p>
    <p>A <italic>Chlamydia</italic>, o <italic>Mycoplasma </italic>e outros agentes causadores de infec&#231;&#245;es respirat&#243;rias agudas s&#227;o pat&#243;genos de alta preval&#234;ncia, de forma que, a partir da idade adulta, a maioria da popula&#231;&#227;o j&#225; apresenta anticorpos nas avalia&#231;&#245;es soroepidemiol&#243;gicas. Por essa raz&#227;o, n&#227;o foi feito o pareamento para idade no grupo-controle, j&#225; que, na idade adulta, admite-se n&#227;o existir rela&#231;&#227;o entre os valores sorol&#243;gicos e a faixa et&#225;ria. Assim, ao serem escolhidos indiv&#237;duos mais jovens para este grupo (doadores de sangue), diminuiu-se tamb&#233;m a possibilidade de doen&#231;a arterial coronariana clinicamente n&#227;o-detect&#225;vel. </p>
    <p>Optou-se pela imunoglobulina da classe IgG porque esta tem vida m&#233;dia de 20 a 30 dias e &#233; o anticorpo (Ac) que melhor expressa a atividade do processo infeccioso, em decorr&#234;ncia de reinfec&#231;&#245;es pr&#233;vias<sup>14</sup>. </p>
    <p>Nos <xref ref-type="fig" rid="grf01">gr&#225;ficos 1</xref> e <xref ref-type="fig" rid="grf02">2</xref>, observa-se, nos pacientes que apresentaram SIMI com supradesnivelamento, uma redu&#231;&#227;o significativa dos t&#237;tulos dos Ac anti-Cp e anti-Mp. Essa redu&#231;&#227;o sugere fortemente que a <italic>Chlamydia</italic> e o <italic>Mycoplasma </italic>presentes na placa ateroscler&#243;tica estiveram em atividade, uma vez que seria extremamente improv&#225;vel que tivesse ocorrido reinfec&#231;&#227;o simult&#226;nea pelos dois agentes.</p>
    <p>Poder-se-ia especular que a pr&#243;pria co-infec&#231;&#227;o da placa ateroscler&#243;tica poderia ter sido o "gatilho" que fez que esses dois agentes tivessem entrado em atividade, desencadeando a cascata inflamat&#243;ria que, por sua vez, levaria ao evento coronariano agudo. </p>
    <p>No grupo sem supradesnivelamento, observou-se apenas uma discreta redu&#231;&#227;o n&#227;o-significativa dos n&#237;veis sorol&#243;gicos anti-Cp, com valores praticamente id&#234;nticos em rela&#231;&#227;o ao Mp. Esses achados sugerem que, nesta forma de SIMI, ocorreria uma reativa&#231;&#227;o infecciosa de menor intensidade, levando a menor dano da placa ateroscler&#243;tica. </p>
    <p>Quando comparados os quatro grupos entre si, utilizando-se as amostras coletadas na primeira fase do estudo, observaram-se valores sorol&#243;gicos mais elevados nos grupos que apresentaram evento coronariano agudo em rela&#231;&#227;o aos outros dois grupos (aterosclerose cr&#244;nica e controle, tanto em rela&#231;&#227;o ao Ac anti-Cp quanto ao anti-Mp). Entretanto, as diferen&#231;as encontradas n&#227;o atingiram signific&#226;ncia estat&#237;stica. </p>
    <p>Tampouco foram observadas diferen&#231;as significativas dos n&#237;veis sorol&#243;gicos entre os grupos aterosclerose cr&#244;nica e controle, tanto para <italic>Chlamydia</italic> quanto para <italic>Mycoplasma</italic>. Esses dados sugerem que a participa&#231;&#227;o do processo infeccioso poderia estar restrita apenas aos mecanismos de instabilidade da placa. Finalmente, demonstraram-se resultados similares entre os valores sorol&#243;gicos encontrados nos grupos controle e aterosclerose cr&#244;nica; entretanto, n&#227;o se pode descartar a possibilidade (a nosso ver remota) de que isso tenha ocorrido porque o grupo-controle j&#225; estaria com um processo ateroscler&#243;tico em andamento.</p>
    <p>Torna-se dif&#237;cil a compara&#231;&#227;o entre os resultados do presente estudo e os demais estudos soroepidemiol&#243;gicos, uma vez que existem importantes diferen&#231;as metodol&#243;gicas entre eles. A grande maioria desses estudos foi retrospectiva<sup>3,5,15-17</sup>, e os poucos prospectivos utilizaram variadas t&#233;cnicas de dosagem de Ac e diferentes crit&#233;rios para positividade sorol&#243;gica<sup>4,6,18</sup>. </p>
    <p>Alguns desses estudos demonstraram que uma alta carga de pat&#243;genos, ao atuar simultaneamente em um mesmo indiv&#237;duo, poderia exacerbar o processo ateroscler&#243;tico<sup>19,20</sup>, o que vem de encontro aos achados do presente estudo. </p>
    <p>
      <bold>Conclus&#245;es</bold>
    </p>
    <p>O presente estudo demonstra associa&#231;&#227;o entre t&#237;tulos de anticorpos anti-Cp e de anti-Mp e doen&#231;a coronariana aguda. Demonstra ainda a normaliza&#231;&#227;o daqueles t&#237;tulos em um per&#237;odo de at&#233; 6 meses, a partir da instabilidade cl&#237;nica do paciente. </p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo foi parcialmente financiado por FAPESP.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de doutorado de Irineu Luiz Maia pelo Instituto do Cora&#231;&#227;o da Faculdade de Medicina da Universidade de S&#227;o Paulo e Faculdade de Medicina de S&#227;o Jos&#233; do Rio Preto.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Irineu Luiz Maia </p>
        <p> Rua Raul de Carvalho 3862, Alto Rio Preto </p>
        <p> 15020-020, S&#227;o Jos&#233; do Rio Preto, SP - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="maia@famerp.com.br">maia@famerp.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 16/11/2007; revisado recebido em 06/05/2008; aceito em 30/05/2008.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Fabricant CG, Fabricant J, Litrenta MM, Minick    CR. Virus-induced atherosclerosis. J Exp Med. 1978; 148 (1): 335-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Virus-induced atherosclerosis</article-title>
          <source>J Exp Med</source>
          <date>
            <year>1978</year>
          </date>
          <fpage>335</fpage>
          <lpage>40</lpage>
          <issue>1</issue>
          <volume>148</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fabricant</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Fabricant</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Litrenta</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Minick</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Libby P, Egan D, Skarlatos S. Roles of infectious    agents in atherosclerosis and restenosis: an assessment of the evidence and    need for future research. Circulation. 1997; 96 (11): 4095-103.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research</article-title>
          <source>Circulation</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>4095</fpage>
          <lpage>103</lpage>
          <issue>11</issue>
          <volume>96</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Egan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Skarlatos</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Saikku P, Leinonen M, Mattila K, Ekman MR,    Nieminen MS, M&#228;kel&#228; PH, et al. Serological evidence of an association    of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial    infarction. Lancet. 1988; 2 (8618): 983-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction</article-title>
          <source>Lancet</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>983</fpage>
          <lpage>6</lpage>
          <issue>8618</issue>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Saikku</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Leinonen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mattila</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ekman</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Nieminen</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>M&#228;kel&#228;</surname>
              <given-names>PH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Saikku P, Leinonen M, Tenkanen L, Linnanm&#228;ki    E, Ekman MR, Manninen V, et al. Chronic Chlamydia pneumoniae infection as a    risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern    Med. 1992; 116 (4): 273-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study</article-title>
          <source>Ann Intern Med</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>273</fpage>
          <lpage>8</lpage>
          <issue>4</issue>
          <volume>116</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Saikku</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Leinonen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tenkanen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Linnanm&#228;ki</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ekman</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Manninen</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Thom DH, Grayston JT, Siscovick DS, Wang SP,    Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae    and angiographically demonstrated coronary artery disease. JAMA. 1992; 268 (1):    68-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease</article-title>
          <source>JAMA</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>68</fpage>
          <lpage>72</lpage>
          <issue>1</issue>
          <volume>268</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Thom</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Grayston</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Siscovick</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Daling</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S,    Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated    with future risk of stroke and cardiovascular disease: a prospective study in    middle-aged to elderly men with treated hypertension. Stroke. 1999; 30 (2):    299-305.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension</article-title>
          <source>Stroke</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>299</fpage>
          <lpage>305</lpage>
          <issue>2</issue>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fagerberg</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gnarpe</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gnarpe</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Agewall</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wikstrand</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Wimmer ML, Sandmann-Strupp R, Saikku P, Haberl    RL. Association of chlamydial infection with cerebrovascular disease. Stroke.    1996; 27 (12): 2207-10.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Association of chlamydial infection with cerebrovascular disease</article-title>
          <source>Stroke</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>2207</fpage>
          <lpage>10</lpage>
          <issue>12</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wimmer</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Sandmann-Strupp</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Saikku</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Haberl</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Higuchi M, Castelli JB, Aiello VD, Palomino    S, Reis MM, Sambiase NV, et al. Great amount of C.pneumoniae in ruptured plaque    vessel segments at autopsy. A comparative study with stable plaques. Arq Bras    Cardiol. 2000; 74 (2): 149-51.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Great amount of C.pneumoniae in ruptured plaque vessel segments at autopsy. A comparative study with stable plaques</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>149</fpage>
          <lpage>51</lpage>
          <issue>2</issue>
          <volume>74</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Higuchi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Castelli</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Aiello</surname>
              <given-names>VD</given-names>
            </name>
            <name>
              <surname>Palomino</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Reis</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Sambiase</surname>
              <given-names>NV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Higuchi ML, Sambiase N, Palomino S, Gutierrez    P, Demarchi LM, Aiello VD, et al. Detection of Mycoplasma pneumoniae and Chlamydia    pneumoniae in ruptured atherosclerotic plaques. Braz J Med Biol Res. 2000; 33    (9): 1023-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Detection of Mycoplasma pneumoniae and Chlamydia pneumoniae in ruptured atherosclerotic plaques</article-title>
          <source>Braz J Med Biol Res</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1023</fpage>
          <lpage>6</lpage>
          <issue>9</issue>
          <volume>33</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Higuchi</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Sambiase</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Palomino</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gutierrez</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Demarchi</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Aiello</surname>
              <given-names>VD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Razin S, Yogev D, Naot Y. Molecular biology    and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev. 1998; 62 (4): 1094-156.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Molecular biology and pathogenicity of mycoplasmas</article-title>
          <source>Microbiol Mol Biol Rev</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1094</fpage>
          <lpage>156</lpage>
          <issue>4</issue>
          <volume>62</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Razin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yogev</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Naot</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Sociedade Brasileira de Cardiologia.Guidelines    of the Brazilian Cardiology Society on unstable angina and myocardial acute    infarction without ST-segment elevation: Part I: Risk stratification and approaches    in the first 12 hours after the patient arrives to the hospital. Arq Bras Cardiol.    2001; 77 (Suppl 2): 3-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Guidelines of the Brazilian Cardiology Society on unstable angina and myocardial acute infarction without ST-segment elevation: Part I</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>3</fpage>
          <lpage>23</lpage>
          <volume>77</volume>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Granato C. Procedimentos operacionais padr&#227;o.:manual    do Laborat&#243;rio Fleury. S&#227;o Paulo: 2005.</mixed-citation>
        <element-citation publication-type="book">
          <source>Procedimentos operacionais padr&#227;o.:manual do Laborat&#243;rio Fleury</source>
          <date>
            <year>2005</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Granato</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Runyon RP. Fundamentals of statistics in    the biological, medical and health sciences. Boston: PWS Publishers; 1985.</mixed-citation>
        <element-citation publication-type="book">
          <source>Fundamentals of statistics in the biological, medical and health sciences</source>
          <date>
            <year>1985</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Runyon</surname>
              <given-names>RP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Parham P. O Sistema Imune. Porto Alegre:    Ed Art M&#233;d; 2001.</mixed-citation>
        <element-citation publication-type="book">
          <source>O Sistema Imune</source>
          <date>
            <year>2001</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Parham</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Mendall MA, Carrington D, Strachan D, Patel    P, Molineaux N, Levi J, et al. Chlamydia pneumoniae: risk factors for seropositivity    and association with coronary heart disease. J Infect. 1995; 30 (2): 121-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease</article-title>
          <source>J Infect</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>121</fpage>
          <lpage>8</lpage>
          <issue>2</issue>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mendall</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Carrington</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Strachan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Molineaux</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Levi</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Blasi F, Cosentini R, Raccanelli R, Massari    FM, Arosio C, Tarsia P, et al. A possible association of Chlamydia pneumoniae    infection and acute myocardial infarction in patients younger than 65 years    of age. Chest. 1997; 112 (2): 309-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A possible association of Chlamydia pneumoniae infection and acute myocardial infarction in patients younger than 65 years of age</article-title>
          <source>Chest</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>309</fpage>
          <lpage>12</lpage>
          <issue>2</issue>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Blasi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cosentini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Raccanelli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Massari</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Arosio</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tarsia</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Thom DH, Wang SP, Grayston JT, Siscovick    DS, Stewart DK, Kronmal RA, et al. Chlamydia pneumoniae strain TWAR antibody    and angiographically demonstrated coronary artery disease. Arterioscler Thromb.    1991; 11 (3): 547-51.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease</article-title>
          <source>Arterioscler Thromb</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>547</fpage>
          <lpage>51</lpage>
          <issue>3</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Thom</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Grayston</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Siscovick</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Kronmal</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Arcari CM, Gaydos CA, Nieto FJ, Krauss M,    Nelson KE. Association between Chlamydia pneumoniae and acute myocardial infarction    in young men in the United States military: the importance of timing of exposure    measurement. Clin Infect Dis. 2005; 40 (8): 1123-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Association between Chlamydia pneumoniae and acute myocardial infarction in young men in the United States military: the importance of timing of exposure measurement</article-title>
          <source>Clin Infect Dis</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1123</fpage>
          <lpage>30</lpage>
          <issue>8</issue>
          <volume>40</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Arcari</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Gaydos</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Nieto</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Krauss</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>KE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Stacey A, Bradlow A. Arcanobacterium haemolyticum    and Mycoplasma pneumoniae co-infection. J Infect. 1999; 38 (1): 41-2.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Arcanobacterium haemolyticum and Mycoplasma pneumoniae co-infection</article-title>
          <source>J Infect</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>41</fpage>
          <lpage>2</lpage>
          <issue>1</issue>
          <volume>38</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stacey</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bradlow</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Holland JF, Frei E. Cancer Medicine. 5th.    ed. Boston: Ed Becker B.C. Inc.; 2000.</mixed-citation>
        <element-citation publication-type="book">
          <source>Cancer Medicine</source>
          <date>
            <year>2000</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Holland</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Frei</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Prevalencia de Chlamydia Pneumoniae y Mycoplasma Pneumoniae en diferentes formas de la enfermedad coronaria</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: Se han investigado diversos agentes infecciosos desde que se evidenci&#243; la asociaci&#243;n entre infecci&#243;n y aterosclerosis, sin embargo esos estudios ofrecen resultados conflictivos. OBJETIVO: Probar la asociaci&#243;n entre t&#237;tulos s&#233;ricos de anticuerpos anti-Chlamydia y anti-Mycoplasma en diferentes formas de s&#237;ndromes coronarios agudos (SCA). M&#201;TODOS: Se dividieron a 126 pacientes en 4 grupos: SCA con elevaci&#243;n del segmento ST (32 pacientes), SCA sin elevaci&#243;n del segmento ST (30 pacientes), enfermedad arterial coronaria cr&#243;nica (30 pacientes) y donadores de sangre sin enfermedad coronaria conocida (34 pacientes - grupo-control). En los primeros dos grupos, muestras de suero se colectaron al ingreso (primeras 24 horas de hospitalizaci&#243;n) y tras 6 meses de seguimiento. En los otros dos grupos, se colect&#243; solamente una muestra basal. En todas las muestras, se dosificaron anticuerpos IgG anti-Chlamydia y anti-Mycoplasma por inmunofluorescencia indirecta. RESULTADOS: Se observaron diferencias significativas entre la medida basal y tras 6 meses de seguimiento en los pacientes con infarto de miocardio con elevaci&#243;n del segmento ST, tanto para Chlamydia (650&#177;115,7 vs 307&#177;47,5, p = 0,0001) como para Mycoplasma (36,5&#177;5,0 vs 21,5&#177;3,5, p = 0,0004). Los grupos con SCA tuvieron niveles s&#233;ricos de anticuerpos anti-Chlamydia y anti-Mycoplasma m&#225;s altos en la dosificaci&#243;n basal, con relaci&#243;n a los pacientes con enfermedad arterial coronaria cr&#243;nica y grupo-control, sin embargo las diferencias obtenidas no tuvieron significancia estad&#237;stica. CONCLUSI&#211;N: El presente estudio revel&#243; asociaci&#243;n entre los t&#237;tulos de anticuerpos anti-Chlamydia y anti-Mycoplasma en la fase aguda de los pacientes con angina inestable o infarto de miocardio.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Chlamydophila pneumoniae</kwd>
        <kwd>mycoplasma pneumoniae</kwd>
        <kwd>aterosclerosis</kwd>
        <kwd>enfermedad de la arteria coronaria</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p><undefined id="tx-body2"/>Prevalencia de <italic><bold>Chlamydia Pneumoniae</bold></italic> y <italic><bold>Mycoplasma Pneumoniae</bold></italic> en diferentes formas de la enfermedad coronaria</p>
      <p>
        <bold>Irineu Luiz Maia<sup>I,II</sup>; Jos&#233; Carlos Nicolau<sup>III</sup>; Maur&#237;cio de Nassau Machado<sup>I,II</sup>; L&#237;lia Nigro Maia<sup>I,II</sup>; Isabela Thomaz Takakura<sup>II</sup>; Paulo Ricardo de Fernando Rocha<sup>II</sup>; Jos&#233; Ant&#244;nio Cordeiro<sup>I</sup>; Jos&#233; Ant&#244;nio Franchini Ramires<sup>III</sup></bold>
      </p>
      <p><sup>I</sup>Faculdade de Medicina de S&#227;o Jos&#233; do Rio Preto (Famerp), S&#227;o Jos&#233; do Rio Preto, SP; S&#227;o Paulo, SP - Brasil</p>
      <p><sup>II</sup>Hospital de Base de S&#227;o Jos&#233; do Rio Preto, S&#227;o Jos&#233; do Rio Preto, SP; S&#227;o Paulo, SP - Brasil</p>
      <p><sup>III</sup>Instituto do Cora&#231;&#227;o - Faculdade de Medicina da Universidade de S&#227;o Paulo (InCor - USP), S&#227;o Jos&#233; do Rio Preto, SP; S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> Se han investigado diversos agentes infecciosos desde que se evidenci&#243; la asociaci&#243;n entre infecci&#243;n y aterosclerosis, sin embargo esos estudios ofrecen resultados conflictivos.</p>
      <p><bold>OBJETIVO:</bold> Probar la asociaci&#243;n entre t&#237;tulos s&#233;ricos de anticuerpos anti-<italic>Chlamydia</italic> y anti-<italic>Mycoplasma</italic> en diferentes formas de s&#237;ndromes coronarios agudos (SCA).</p>
      <p><bold>M&#201;TODOS:</bold> Se dividieron a 126 pacientes en 4 grupos: SCA con elevaci&#243;n del segmento ST (32 pacientes), SCA sin elevaci&#243;n del segmento ST (30 pacientes), enfermedad arterial coronaria cr&#243;nica (30 pacientes) y donadores de sangre sin enfermedad coronaria conocida (34 pacientes - grupo-control). En los primeros dos grupos, muestras de suero se colectaron al ingreso (primeras 24 horas de hospitalizaci&#243;n) y tras 6 meses de seguimiento. En los otros dos grupos, se colect&#243; solamente una muestra basal. En todas las muestras, se dosificaron anticuerpos IgG anti-<italic>Chlamydia</italic> y anti-<italic>Mycoplasma</italic> por inmunofluorescencia indirecta.</p>
      <p><bold>RESULTADOS:</bold> Se observaron diferencias significativas entre la medida basal y tras 6 meses de seguimiento en los pacientes con infarto de miocardio con elevaci&#243;n del segmento ST, tanto para <italic>Chlamydia</italic> (650&#177;115,7 <italic>vs</italic> 307&#177;47,5, p = 0,0001) como para <italic>Mycoplasma</italic> (36,5&#177;5,0 <italic>vs</italic> 21,5&#177;3,5, p = 0,0004). Los grupos con SCA tuvieron niveles s&#233;ricos de anticuerpos anti-<italic>Chlamydia</italic> y anti-<italic>Mycoplasma</italic> m&#225;s altos en la dosificaci&#243;n basal, con relaci&#243;n a los pacientes con enfermedad arterial coronaria cr&#243;nica y grupo-control, sin embargo las diferencias obtenidas no tuvieron significancia estad&#237;stica.</p>
      <p><bold>CONCLUSI&#211;N:</bold> El presente estudio revel&#243; asociaci&#243;n entre los t&#237;tulos de anticuerpos anti-<italic>Chlamydia</italic> y anti-<italic>Mycoplasma </italic>en la fase aguda de los pacientes con angina inestable o infarto de miocardio.</p>
      <p><bold>Palabras clave:</bold><italic>Chlamydophila pneumoniae</italic>, <italic>mycoplasma pneumoniae</italic>, aterosclerosis, enfermedad de la arteria coronaria.</p>
      <p>(ClinicalTrials.gov - NCT00561028)</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>Desde 1978, cuando se evidenci&#243; por primera vez la asociaci&#243;n entre infecci&#243;n y aterosclerosis<sup>1</sup>, se han investigado diversos agentes infecciosos<sup>2</sup>. Entre esos, es la <italic>Chlamydia pneumoniae </italic>(Cp) que presenta mayores evidencias en cuanto a su participaci&#243;n en la enfermedad ateroscler&#243;tica estable, en el infarto agudo de miocardio (IAM) y en el accidente cerebrovascular (ACV)<sup>3-7</sup>.</p>
      <p>Sin embargo, los resultados contradictorios de los estudios que probaron los efectos de antibi&#243;ticos anti-Cp en la reducci&#243;n de eventos cardiovasculares pusieron en duda la participaci&#243;n de infecci&#243;n y, m&#225;s espec&#237;ficamente, de la Cp en la enfermedad ateroscler&#243;tica.</p>
      <p>En 2000, Higuchi et al<sup>8,9</sup>, en estudio de piezas de necropsia, adem&#225;s de confirmar un alta cantidad de c&#233;lulas infectadas por la Cp en placas ateroscler&#243;ticas rotas, fueron los primeros a evidenciar la presencia de un otro agente infeccioso en el local, posteriormente identificado como <italic>Mycoplasma pneumoniae </italic>(Mp)<sup>8,9</sup>.</p>
      <p>Ese agente infeccioso se comporta como superant&#237;geno y necesita del colesterol para sobrevivir, una vez que su membrana se constituye de esa sustancia<sup>10</sup>. Desde el punto de vista fisiopatol&#243;gico, una hip&#243;tesis atrayente ser&#237;a la de que el Mp funcionaria como un "gatillo" para la activaci&#243;n de la Cp, promoviendo as&#237; la instabilidad de la placa ateroscler&#243;tica coronaria. </p>
      <p>Se planific&#243; ese estudio-piloto para evaluar, por medio de investigaci&#243;n serol&#243;gica, el rol de esos dos agentes bacterianos en el desencadenamiento de eventos isqu&#233;micos coronarios agudos.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>
        <bold>Dise&#241;o del estudio</bold>
      </p>
      <p>El Comit&#233; de &#201;tica en Investigaci&#243;n local aprob&#243; este estudio y todos los pacientes firmaron el formulario de consentimiento informado.</p>
      <p>En el per&#237;odo de marzo de 2002 a noviembre de 2004, se incluyeron de forma prospectiva a 138 pacientes, de ellos:</p>
      <p>a) 34 pacientes eran portadores de IAM con supradesnivel del segmento ST (edad promedio de 55,1&#177;1,7 a&#241;os, con un 73,5% del sexo masculino);</p>
      <p>b) 40 pacientes eran portadores de angina inestable o IAM sin supradesnivel del segmento ST (edad promedio de 60,1&#177;2,1 a&#241;os, con un 52,5% del sexo masculino); </p>
      <p>c) 30 pacientes eran portadores de aterosclerosis cr&#243;nica, asintom&#225;ticos o portadores de angina estable (edad promedio de 65,9&#177;2,0 a&#241;os, con un 63,3% del sexo masculino);</p>
      <p>d) 34 individuos no ten&#237;an enfermedad coronaria conocida, eran donadores de sangre (edad promedio de 42,5&#177;1,2 a&#241;os, con un 64,7% del sexo masculino).</p>
      <p>
        <bold>Objetivo primario</bold>
      </p>
      <p>El objetivo principal del estudio fue probar la asociaci&#243;n entre t&#237;tulos serol&#243;gicos de anticuerpos anti-<italic>Chlamydia pneumoniae </italic>y anti-<italic>Mycoplasma pneumoniae </italic>(anti-Cp y anti-Mp) y s&#237;ndromes isqu&#233;micos mioc&#225;rdicos instables (SIMI).</p>
      <p>
        <bold>Criterios de inclusi&#243;n</bold>
      </p>
      <p>Se incluyeron a pacientes de ambos sexos con edad superior a 18 a&#241;os, tras firmar el formulario de consentimiento informado. Los diferentes grupos se definieron de la forma que sigue a continuaci&#243;n:</p>
      <p>
        <bold>a) SIMI con supradesnivel del segmento ST</bold>
      </p>
      <p>Pacientes que presentaban dolor con caracter&#237;sticas anginosas <underline>&lt;</underline> 24 horas de evoluci&#243;n, que completan al menos dos de los siguientes criterios de IAM: </p>
      <p>&#149; <italic>Cl&#237;nicos -</italic> Dolor retroesternal de fuerte intensidad y car&#225;cter opresivo, duraci&#243;n superior a 20 minutos, que no cedi&#243; con el uso de nitratos.</p>
      <p>&#149; <italic>Electrocardiogr&#225;ficos -</italic> Supradesnivel del segmento ST <underline>&gt;</underline> 1 mm en al menos dos derivaciones perif&#233;ricas y/o supradesnivel del segmento ST <underline>&gt;</underline> 2 mm en al menos dos derivaciones consecutivas precordiales y/o presencia de bloqueo de rama izquierda.</p>
      <p>&#149; <italic>Marcadores de necrosis mioc&#225;rdica -</italic> Elevaci&#243;n de al menos dos veces en relaci&#243;n a los valores normales de la CKMB actividad (normal hasta 25 U/l) y/o troponina T (normal hasta 0,010 ng/ml).</p>
      <p>
        <bold>b) SIMI sin supradesnivel del segmento ST</bold>
      </p>
      <p>Pacientes que presentaban dolor con caracter&#237;sticas anginosas <underline>&lt;</underline> 24 horas de evoluci&#243;n, con (IAM sin supradesnivel del segmento ST) o sin (angina inestable) elevaci&#243;n de los biomarcadores de necrosis mioc&#225;rdica (CKMB y/o troponina T). En ese grupo, se seleccionaron solamente a pacientes de alto riesgo, de acuerdo con la clasificaci&#243;n de la Sociedad Brasile&#241;a de Cardiolog&#237;a (SBC) <sup>11</sup>.</p>
      <p>&#149; Edad &gt; 75 a&#241;os.</p>
      <p>&#149; Dolor progresivo s&#237;ntomas en las &#250;ltimas 48 horas.</p>
      <p>&#149; Dolor prolongado (&gt; 20 min), en reposo.</p>
      <p>&#149; Edema pulmonar, empeoramiento o surgimiento de soplo de regurgitaci&#243;n mitral, B3, hipotensi&#243;n, bradicardia y taquicardia.</p>
      <p>&#149; Infradesnivel del segmento ST <underline>&gt;</underline> 0,5 mm (asociado o no a angina), alteraci&#243;n din&#225;mica del ST, bloqueo completo de rama, nuevo o presumidamente nuevo. Taquicardia ventricular sostenida.</p>
      <p>&#149; Marcadores de isquemia acentuadamente elevados (&gt; percentil 99).</p>
      <p>
        <bold>c) Grupo aterosclerosis cr&#243;nica</bold>
      </p>
      <p>Pacientes con enfermedad ateroscler&#243;tica coronaria cr&#243;nica asintom&#225;tica o con angina estable. La presencia de la enfermedad se defini&#243; por los siguientes criterios:</p>
      <p>&#149; IAM previo; y/<italic>o</italic></p>
      <p>&#149; Revascularizaci&#243;n quir&#250;rgica del miocardio previa; y/<italic>o</italic></p>
      <p>&#149; Intervenci&#243;n coronaria percut&#225;nea previa; y/<italic>o</italic></p>
      <p>&#149; Cineangiocoronariograf&#237;a previa evidenciando lesiones obstructivas de arterias coronarias.</p>
      <p>
        <bold>d) Grupo-control</bold>
      </p>
      <p>Individuos seleccionados de modo aleatorio, a partir de los donadores de sangre del Hospital de Base, y que negaban la presencia de cualquier enfermedad ateroscler&#243;tica conocida.</p>
      <p>
        <bold>Criterios de exclusi&#243;n</bold>
      </p>
      <p>Se excluyeron a los pacientes que presentaron al menos uno de los siguientes criterios:</p>
      <p>&#149; Dificultad de comprensi&#243;n del formulario de consentimiento informado;</p>
      <p>&#149; Rechazo a firmar el formulario de consentimiento informado;</p>
      <p>&#149; Imposibilidad de regresar al seguimiento del estudio;</p>
      <p>&#149; Edad inferior a 18 a&#241;os;</p>
      <p>&#149; Tiempo de evoluci&#243;n &gt; 24 horas;</p>
      <p>&#149; Infecci&#243;n activa;</p>
      <p>&#149; Uso de antimicrobianos en los &#250;ltimos 30 d&#237;as;</p>
      <p>&#149; Enfermedades terminales.</p>
      <p>
        <bold>Metodolog&#237;a de la colecta sangu&#237;nea</bold>
      </p>
      <p>En los grupos portadores de SIMI con y sin supradesnivel ST, se colectaron muestras sangu&#237;neas en dos ocasiones, la primera durante el evento agudo y la segunda tras 6 meses. En los otros dos grupos (aterosclerosis cr&#243;nica y control), se colectaron dichas muestras solamente una vez. Como la vida media de los anticuerpos de la clase IgG es de 30 d&#237;as, la colecta tras 6 meses del evento agudo busc&#243; reflejar los valores basales de una persona infectada cr&#243;nicamente, tanto por la Cp como por el Mp.</p>
      <p>En todas las muestras, se dosificaron los t&#237;tulos de anticuerpos anti-Cp y anti-Mp de la clase IgG con los resultados expresados por el mayor valor de la diluci&#243;n en que la reacci&#243;n fue positiva. </p>
      <p>
        <bold>An&#225;lisis laboratoriales</bold>
      </p>
      <p>Las pruebas serol&#243;gicas se llevaron a cabo por un &#250;nico y experimentado examinador, de forma ciega, adem&#225;s de emplearse la t&#233;cnica de inmunofluorescencia indirecta<sup>12</sup>.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Los datos categ&#243;ricos est&#225;n detallados en n&#250;meros absolutos y porcentajes, y las variables continuas en promedio &#177; error est&#225;ndar (EE) para una mejor aclaraci&#243;n. Las variables continuas no tuvieron distribuci&#243;n gaussiana y se evaluaron por pruebas no param&#233;tricas (Kruskal-Wallis y Wilcoxon)<sup>13</sup>. Gr&#225;ficos <italic>Box Plot</italic> est&#225;n presentados en mediana e intercuartiles. Valores p &lt; 0,05 se consideraron como estad&#237;sticamente significativos (a dos colas). El <italic>software</italic> utilizado para el an&#225;lisis estad&#237;stico fue el StatsDirect Statistics Software v. 2.6.5.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>El tama&#241;o de la muestra recomendado fue de 30 pacientes por grupo, totalizando 120 pacientes. </p>
      <p>En el transcurrir del estudio, 8 pacientes fallecieron, con 2 del grupo SIMI con supra ST y 6 del grupo SIMI sin supra ST. Cuatro pacientes del grupo SIMI sin supra ST no comparecieron a los regresos pre agendados y tras varias tentativas mal sucedidas de contacto, se les consideraron como p&#233;rdida de seguimiento, y, por lo tanto, en esos casos, no fue posible colectar la segunda serolog&#237;a. </p>
      <p>Esas p&#233;rdidas se las remplazaron, con la inclusi&#243;n de un total de 138 pacientes: 34 en el grupo SIMI con supra ST; 40 pacientes en el grupo SIMI sin supra ST; 30 pacientes en el grupo aterosclerosis cr&#243;nica y 34 individuos en el grupo-control. Solamente se incluyeron en todos los an&#225;lisis realizados en el estudio a los pacientes que realizaron todas las serolog&#237;as planificadas para su grupo. </p>
      <p>
        <bold>Caracter&#237;sticas cl&#237;nicas de los pacientes</bold>
      </p>
      <p>En la <xref ref-type="table" rid="tab01-body2">Tabla 1</xref>, est&#225;n relacionadas las caracter&#237;sticas cl&#237;nicas de los 126 pacientes que realizaron todas las serolog&#237;as planificadas. </p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gt01-es.jpg"/></table-wrap>
      <p>Vale destacar el alta prevalencia de factores de riesgo encontrados en el grupo aterosclerosis cr&#243;nica (un 83,3% eran hipertensos, un 53,3% tabaquistas y el 90% dislipid&#233;micos).</p>
      <p>
        <bold>Comparaci&#243;n entre las serolog&#237;as obtenidas al ingreso y tras 6 meses de la internaci&#243;n en los grupos con y sin supradesnivel del segmento ST</bold>
      </p>
      <p>En los <xref ref-type="fig" rid="grf01-body2">gr&#225;ficos 1</xref> y <xref ref-type="fig" rid="grf02-body2">2</xref>, se evidenciaron los valores serol&#243;gicos colectados en la fase aguda del evento coronario y tras 6 meses, en los grupos con y sin supradesnivel del segmento ST, con ese an&#225;lisis el objetivo principal del estudio. </p>
      <fig id="grf01-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gf01-es.jpg"/></fig>
      <fig id="grf02-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gf02-es.jpg"/></fig>
      <p>Los pacientes portadores de SIMI con supra presentaron significativa reducci&#243;n de los t&#237;tulos serol&#243;gicos en las colectas realizadas tras 6 meses de la internaci&#243;n, tanto en relaci&#243;n con la Cp (p = 0,0001) como con relaci&#243;n a la Mp (p = 0,0004).</p>
      <p>No se observ&#243; igual comportamiento serol&#243;gico en el grupo sin supradesnivel del segmento ST, tanto para la Cp como para el Mp (p = 0,27 y 0,99, respectivamente). </p>
      <p>
        <bold>Comparaci&#243;n entre los valores serol&#243;gicos realizados al inicio del estudio</bold>
      </p>
      <p>Los <xref ref-type="fig" rid="grf03-body2">gr&#225;ficos 3</xref> y <xref ref-type="fig" rid="grf04-body2">4</xref> comparan las diferencias serol&#243;gicas entre los diferentes grupos analizados (primera muestra serol&#243;gica). </p>
      <fig id="grf03-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gf03-es.jpg"/></fig>
      <fig id="grf04-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gf04-es.jpg"/></fig>
      <p>Se puede notar, en los grupos que presentaron isquemia mioc&#225;rdica aguda (SIMI con y sin supra ST), valores serol&#243;gicos m&#225;s elevados comparados a los grupos que no tuvieron evento agudo (aterosclerosis cr&#243;nica y control), tanto en lo que toca a la Cp como al Mp, aunque esas diferencias no hayan alcanzado significancia estad&#237;stica. </p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>El presente estudio fue motivado por la necesidad de se evaluar, cl&#237;nicamente, la presencia concomitante del <italic>Mycoplasma pneumoniae y de la Chlamydia pneumoniae</italic> en lesiones ateromatosas coronarias, descrita previamente por Higuchi et al<sup>9</sup> en hallazgos de necropsia.</p>
      <p>La <italic>Chlamydia</italic>, el <italic>Mycoplasma y</italic> otros agentes causadores de infecciones respiratorias agudas son pat&#243;genos de alta prevalencia, de forma que, desde la edad adulta, la mayor&#237;a de la poblaci&#243;n ya presenta anticuerpos en las evaluaciones seroepidemiol&#243;gicas. Por esa raz&#243;n, no se llev&#243; a cabo el emparejamiento para edad en el grupo-control, ya que, en la edad adulta, se admite no existir relaci&#243;n entre los valores serol&#243;gicos y el grupo de edad. De esa manera, al elegirse a los individuos m&#225;s j&#243;venes para este grupo (donadores de sangre), se reduzco tambi&#233;n la posibilidad de enfermedad arterial coronaria cl&#237;nicamente no-detectable. </p>
      <p>Se opt&#243; por la inmunoglobulina de la clase IgG porque &#233;sta tiene promedio de vida de 20 a 30 d&#237;as y es el anticuerpo (Ac) que mejor expresa la actividad del proceso infeccioso, en consecuencia de reinfecciones previas<sup>14</sup>. </p>
      <p>En los <xref ref-type="fig" rid="grf01-body2">gr&#225;ficos 1</xref> y <xref ref-type="fig" rid="grf02-body2">2</xref>, se observa, en los pacientes que presentaron SIMI con supra, una reducci&#243;n significativa de los t&#237;tulos de los Ac anti-Cp y anti-Mp. Esa reducci&#243;n sugiere fuertemente que la <italic>Chlamydia</italic> y el <italic>Mycoplasma </italic>presentes en la placa ateroscler&#243;tica estuvieron en actividad, una vez que ser&#237;a extremamente improbable que tuviera ocurrido reinfecci&#243;n simult&#225;nea por los dos agentes.</p>
      <p>Se podr&#237;a especular que la propia coinfecci&#243;n de la placa ateroscler&#243;tica podr&#237;a haber sido el "gatillo" que indujo esos dos agentes a entrar en actividad, desencadenando la cascada inflamatoria que, a su vez, conllevar&#237;a el evento coronario agudo. </p>
      <p>En el grupo sin supra, se observ&#243; s&#243;lo una discreta reducci&#243;n no significativa de los niveles serol&#243;gicos anti-Cp, con valores pr&#225;cticamente id&#233;nticos con relaci&#243;n al Mp. Esos hallazgos sugieren que, en esta forma de SIMI, ocurrir&#237;a una reactivaci&#243;n infecciosa de menor intensidad, resultando un menor da&#241;o de la placa ateroscler&#243;tica. </p>
      <p>Cuando comparados los cuatro grupos entre si, utiliz&#225;ndose las muestras colectadas en la primera fase del estudio, se observaron valores serol&#243;gicos m&#225;s elevados en los grupos que presentaron evento coronario agudo respecto a los otros dos grupos (aterosclerosis cr&#243;nica y control, tanto en relaci&#243;n con el Ac anti-Cp como el anti-Mp). Sin embargo, las diferencias encontradas no alcanzaron significancia estad&#237;stica. </p>
      <p>Tampoco se observaron diferencias significativas de los niveles serol&#243;gicos entre los grupos aterosclerosis cr&#243;nica y control, tanto para <italic>Chlamydia</italic> como para <italic>Mycoplasma</italic>. Esos datos sugieren que la participaci&#243;n del proceso infeccioso podr&#237;a estar restricta s&#243;lo a los mecanismos de inestabilidad de la placa. Por fin, se evidencian resultados semejantes entre los valores serol&#243;gicos encontrados en los grupos control y la aterosclerosis cr&#243;nica; sin embargo, no se puede descartar la posibilidad (a nuestro ver, remota) de que eso haya ocurrido porque el grupo-control ya estar&#237;a con un proceso ateroscler&#243;tico en marcha.</p>
      <p>La comparaci&#243;n entre los resultados del presente estudio y los dem&#225;s estudios seroepidemiol&#243;gicos se vuelve dif&#237;cil, una vez que hay importantes diferencias metodol&#243;gicas entre ellos. La gran mayor&#237;a de esos estudios fue retrospectiva<sup>3,5,15-17</sup> y los pocos estudios prospectivos utilizaron variadas t&#233;cnicas de dosificaci&#243;n de Ac y distintos criterios para positividad serol&#243;gica<sup>4,6,18</sup>.</p>
      <p>Algunos de eso estudios revelaron que un alta carga de pat&#243;genos, al actuar simult&#225;neamente en un mismo individuo, podr&#237;a exacerbar el proceso ateroscler&#243;tico<sup>19,20</sup>, lo que contradice los hallazgos del presente estudio. </p>
      <p>
        <bold>Conclusiones</bold>
      </p>
      <p>El presente estudio evidencia la asociaci&#243;n entre t&#237;tulos de anticuerpos anti-Cp y de anti-Mp y enfermedad coronaria aguda. Revela a&#250;n la normalizaci&#243;n de aquellos t&#237;tulos en un per&#237;odo de hasta 6 meses, desde la inestabilidad cl&#237;nica del paciente. </p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio fue parcialmente financiado por FINEP/Petrobras/CNPQ.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de doctorado de Irineu Luiz Maia, por el Instituto do Cora&#231;&#227;o, Facultad de Medicina de la Universidad de S&#227;o Paulo y Facultad de Medicina de S&#227;o Jos&#233; do Rio Preto.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Prevalence of Chlamydia Pneumoniae and Mycoplasma Pneumoniae in different forms of coronary disease</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Several infectious agents have been investigated since the association between atherosclerosis and infection was demonstrated; however, the results of these studies are contradictory. OBJECTIVE: To test the association between serum titers of anti-Chlamydia and anti-Mycoplasma antibodies in different forms of acute coronary syndromes (ACS). METHODS: One hundred and twenty-six patients were divided in 4 groups: ACS with ST- segment elevation (32 patients), ACS without ST-segment elevation (30 patients), chronic coronary artery disease (30 patients) and blood donors without known coronary disease (34 patients - control group). In the two first groups, serum samples were collected at hospital admission (first 24 hours of hospitalization) and after a 6-month follow-up. In the other two groups, only a basal sample was collected. Anti-Chlamydia and anti-Mycoplasma antibodies were measured by indirect immunofluorescence in all samples. RESULTS: Significant differences were observed between the basal sample and the one measured after a 6-month follow-up in patients with myocardial infarction with ST-segment elevation for Chlamydia (650&#177;115.7 versus 307&#177;47.5, p=0.0001) as well as Mycoplasma (36.5&#177;5.0 versus 21.5&#177;3.5, p=0.0004). The groups with ACS had higher anti-Chlamydia and anti-Mycoplasma serum antibody levels in the basal measurement, when compared to the patients with chronic coronary disease and the control group, but the differences were not statistically significant. CONCLUSION: The present study showed an association between the serum titers of anti-Chlamydia and anti-Mycoplasma antibodies in the acute phase of patients with unstable angina or myocardial infarction.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Chlamydophila pneumoniae</kwd>
        <kwd>mycoplasma pneumoniae</kwd>
        <kwd>atherosclerosis</kwd>
        <kwd>coronary artery disease</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="tx-body3">
          <label>
            <bold>Prevalence of <italic>Chlamydia Pneumoniae</italic> and <italic>Mycoplasma Pneumoniae</italic> in different forms of coronary disease</bold>
          </label>
          <p>
            <bold>Irineu Luiz Maia<sup>I, II</sup>; Jos&#233; Carlos Nicolau<sup>III</sup>; Maur&#237;cio de Nassau Machado<sup>I, II</sup>; L&#237;lia Nigro Maia<sup>I, II</sup>; Isabela Thomaz Takakura<sup>II</sup>; Paulo Ricardo de Fernando Rocha<sup>II</sup>; Jos&#233; Ant&#244;nio Cordeiro<sup>I</sup>; Jos&#233; Ant&#244;nio Franchini Ramires<sup>III</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Faculdade de Medicina de S&#227;o Jos&#233; do Rio Preto (Famerp), S&#227;o Jos&#233; do Rio Preto, SP</p>
      <p><sup>II</sup>Hospital de Base de S&#227;o Jos&#233; do Rio Preto, S&#227;o Jos&#233; do Rio Preto, SP</p>
      <p><sup>III</sup>Instituto do Cora&#231;&#227;o - Faculdade de Medicina da Universidade de S&#227;o Paulo (InCor &#150; USP), S&#227;o Jos&#233; do Rio Preto, SP; S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Several infectious agents have been investigated since the association between atherosclerosis and infection was demonstrated; however, the results of these studies are contradictory.</p>
      <p><bold>OBJECTIVE:</bold> To test the association between serum titers of anti-<italic>Chlamydia</italic> and anti-<italic>Mycoplasma</italic> antibodies in different forms of acute coronary syndromes (ACS).</p>
      <p><bold>METHODS:</bold> One hundred and twenty-six patients were divided in 4 groups: ACS with ST- segment elevation (32 patients), ACS without ST-segment elevation (30 patients), chronic coronary artery disease (30 patients) and blood donors without known coronary disease (34 patients - control group). In the two first groups, serum samples were collected at hospital admission (first 24 hours of hospitalization) and after a 6-month follow-up. In the other two groups, only a basal sample was collected. Anti-<italic>Chlamydia</italic> and anti-<italic>Mycoplasma</italic> antibodies were measured by indirect immunofluorescence in all samples.</p>
      <p><bold>RESULTS:</bold> Significant differences were observed between the basal sample and the one measured after a 6-month follow-up in patients with myocardial infarction with ST-segment elevation for <italic>Chlamydia</italic> (650&#177;115.7 versus 307&#177;47.5, p=0.0001) as well as <italic>Mycoplasma</italic> (36.5&#177;5.0 versus 21.5&#177;3.5, p=0.0004). The groups with ACS had higher anti-<italic>Chlamydia</italic> and anti-<italic>Mycoplasma</italic> serum antibody levels in the basal measurement, when compared to the patients with chronic coronary disease and the control group, but the differences were not statistically significant.</p>
      <p><bold>CONCLUSION:</bold> The present study showed an association between the serum titers of anti-<italic>Chlamydia</italic> and anti-<italic>Mycoplasma</italic> antibodies in the acute phase of patients with unstable angina or myocardial infarction. </p>
      <p><bold>Key words:</bold><italic>Chlamydophila pneumoniae; mycoplasma pneumoniae</italic>; atherosclerosis; coronary artery disease.</p>
      <p>(ClinicalTrials.gov - NCT00561028).</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Since 1978, when the association between infection and atherosclerosis was first demonstrated<sup>1</sup>, several infectious agents have been investigated<sup>2</sup>. Among these, <italic>Chlamydia pneumoniae </italic>(Cp) is the one that presents higher evidence of its participation in stable atherosclerotic disease, acute myocardial infarction (AMI) and cerebrovascular accident (CVA)<sup>3-7</sup>.</p>
      <p>However, the contradictory results of the studies that tested the effects of anti-Cp antibiotics on the decrease of cardiovascular events, raised some doubts about the participation of the infection and, more specifically, of Cp in atherosclerotic disease. </p>
      <p>Higuchi et al<sup>8,9</sup>, in a study of necropsy specimens in 2000, confirmed a high number of cells infected by Cp in atherosclerotic plaques, also demonstrating for the first time the presence of another infectious agent in the site, later identified as <italic>Mycoplasma pneumoniae </italic>(Mp)<sup>8,9</sup>. </p>
      <p>This infectious agent behaves as super-antigen and needs cholesterol to survive, as its membrane is comprised of this substance<sup>10</sup>. From the physiopathological point of view, an interesting hypothesis is that the Mp would work as "trigger" to activate the Cp, thus promoting the destabilization of the coronary atherosclerotic plaque. </p>
      <p>This pilot study was planned to evaluate, through a serological investigation, the role of these two bacterial agents in the triggering of acute coronary ischemic events. </p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>
        <bold>Study design</bold>
      </p>
      <p>This study was approved by the local Ethics Committee in Research and all patients signed the free and informed consent form prior to study enrollment. </p>
      <p> From March 2002 to November 2004, a total of 138 patients were prospectively included, as follows:</p>
      <p>a) 34 patients with AMI and ST-segment elevation (mean age 55.1&#177;1.7 years, with 73.5% of the male sex);</p>
      <p>b) 40 patients with unstable angina or AMI without ST-segment elevation (mean age 60.1&#177;2.1 years, with 52.5% of the male sex); </p>
      <p>c) 30 patients with chronic atherosclerosis, asymptomatic, or with stable angina (mean age 65.9&#177;2.0 years, with 63.3% of the male sex);</p>
      <p>d) 34 individuals without known coronary disease who were blood donors, (mean age 42.5&#177;1.2 years, with 64.7% of the male sex).</p>
      <p>
        <bold>Primary objective</bold>
      </p>
      <p>The main objective of study was to test the association between serological titers of anti-<italic>Chlamydia pneumoniae </italic>and anti-<italic>Mycoplasma pneumoniae </italic>(Anti-Cp e Anti-Mp) antibodies and Acute Coronary Syndrome (ACS).</p>
      <p>
        <bold>Inclusion criteria</bold>
      </p>
      <p>Patients of both sexes, aged 18 and older, were included in the study after signing the informed consent form. The different groups were thus defined:</p>
      <p>
        <bold>a) ACS with ST-Segment Elevation </bold>
      </p>
      <p>This group consisted of patients that presented pain with characteristics of angina <underline>&lt;</underline> 24 hours of evolution that met at least two of the following AMI criteria:</p>
      <p>&#149; <italic>Clinical:</italic> high-intensity and oppressive retrosternal pain, lasting longer than 20 minutes, which did not respond to nitrates;</p>
      <p>&#149; <italic>Electrocardiographic:</italic> ST-segment elevation <underline>&gt;</underline> 1mm in at least two peripheral derivations and/or ST-segment elevation <underline>&gt;</underline> 2 mm in at least two consecutive precordial derivations and/or presence of left branch block. </p>
      <p>&#149; <italic>Myocardial necrosis marker: </italic>at least two-fold increase in relation to normal values of CKMB activity (normal up to 25U/l) and/or Troponin T (normal up to 0.010 ng/ml).</p>
      <p>
        <bold>b) ACS without ST-Segment Elevation</bold>
      </p>
      <p>This group consisted of patients that presented pain with characteristics of angina <underline>&gt;</underline> 24 hours of evolution with (AMI without ST-Segment Elevation) or without (unstable angina) increase in biomarkers of myocardial necrosis (CKMB and/or troponin T. </p>
      <p>Only high-risk patients were selected from this group, according to the classification of the Brazilian Society of Cardiology<sup>11</sup>.</p>
      <p>&#149; Age &gt; 75 years</p>
      <p>&#149; Progressive pain, symptoms in the last 48 hrs;</p>
      <p>&#149; Prolonged pain (&gt; 20 min.), at rest;</p>
      <p>&#149; Pulmonary edema, worsening or onset of mitral regurgitation murmur, B3, hypotension, bradycardia and tachycardia.</p>
      <p>&#149; ST segment depression <underline>&gt;</underline> 0.5 mm (associated or not with angina), dynamic ST segment alteration, complete branch block, new or presumably new. Sustained ventricular tachycardia </p>
      <p>&#149; Extremely elevated ischemia markers (&gt;99<sup>th</sup> percentile)</p>
      <p>
        <bold>c) Chronic atherosclerosis group</bold>
      </p>
      <p>Patients with chronic coronary atherosclerotic disease or with stable angina. The presence of the disease was defined by the following criteria: </p>
      <p>&#149; Previous AMI and/or;</p>
      <p>&#149; Previous surgical myocardial revascularization and/or; </p>
      <p>&#149; Previous percutaneous coronary intervention and/or;</p>
      <p>&#149; Previous coronary angiography demonstrating obstructive lesions of coronary arteries.</p>
      <p>
        <bold>d) Control group</bold>
      </p>
      <p>Individuals randomly selected from blood donors at Hospital de Base, who denied the presence of any known atherosclerotic disease. </p>
      <p>
        <bold>Exclusion criteria </bold>
      </p>
      <p>Patients that presented at least one of the following criteria were excluded: </p>
      <p>&#149; Difficulty to understand the informed consent form; </p>
      <p>&#149; Refusal to sign the informed consent form; </p>
      <p>&#149; Impossibility to return for the study follow-up; </p>
      <p>&#149; Age younger than 18 years;</p>
      <p>&#149; Time of evolution &gt; 24 hours;</p>
      <p>&#149; Active infection;</p>
      <p>&#149; Use of antimicrobial agents on the last 30 days;</p>
      <p>&#149; Terminal diseases.</p>
      <p>
        <bold>Blood collection methodology</bold>
      </p>
      <p>In the groups with ACS with and without ST-segment elevation, blood samples were collected at two occasions, the first during the acute event and the second six months later. In the other two groups (chronic atherosclerosis and control groups), these samples were collected only once. As the half-life of the IgG antibodies is 30 days, the collection six months after the acute event aimed at reflecting the basal values of an individual chronically infected by Cp as well as by Mp. </p>
      <p>The IgG anti-Cp and anti-Mp antibodies were measured in all samples and the results were expressed by the highest dilution value in which the reaction was positive. </p>
      <p>
        <bold>Laboratory assessment</bold>
      </p>
      <p>The serological tests were performed by a single, blinded and experienced examiner, using the indirect immunofluorescence technique<sup>12</sup>.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>The categorical data are presented as absolute numbers and percentages ad the continuous variables as means &#177; standard error (SE) for clarity. The continuous variables did not have a Gaussian distribution and were assessed by non-parametric tests (Kruskal-Wallis and Wilcoxon)<sup>13</sup>. Box plot charts are presented in medians and interquartiles; <italic>p</italic> values &lt; 0.05 were considered statistically significant (two-tailed). The software used for the statistical analysis was StatsDirect Statistics Software, v. 2.6.5.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>The recommended sample size consisted of 30 patients per group, totaling 120 patients. </p>
      <p>Eight patients died during the study: 2 from the ACS group with ST elevation and six from the ACS group without ST elevation. Four patients from the ACS without ST elevation did not attend the pre-scheduled follow-up appointments and, after several unsuccessful attempts to contact them, they were considered as lost to follow-up and, therefore, it was not possible to collect the second blood sample in these cases. </p>
      <p>These losses were replaced and a total of 138 patients were included in the study: 34 in the ACS group with ST elevation; 40 patients in the ACS group without ST elevation; 30 patients in the chronic atherosclerosis group and 34 normal individuals in the control group. Only patients that were submitted to all planned serologic assessments for the respective group were included in all the study analyses. </p>
      <p>
        <bold>Clinical characteristics of the patients</bold>
      </p>
      <p><xref ref-type="table" rid="tab01-body3">Table 1</xref> shows the clinical characteristics of the 126 patients that underwent all planned serologic assessments. It is worth mentioning the high prevalence of risk factors found in the chronic atherosclerosis group 83.3% were hypertensive, 53.3% were smokers and 90% presented dyslipidemia).</p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gt01-en.jpg"/></table-wrap>
      <p>
        <bold>Comparison between the serologic analyses obtained at admission and 6 months after hospital admission in the groups with and without ST-segment elevation</bold>
      </p>
      <p><xref ref-type="fig" rid="cht01-body3">Charts 1</xref> and <xref ref-type="fig" rid="cht02-body3">2</xref> demonstrate the serologic values obtained at the acute phase of the coronary event and six months after it, in the groups with and without ST-segment elevation. This analysis was the main objective of the study.</p>
      <fig id="cht01-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gf01-en.jpg"/></fig>
      <fig id="cht02-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gf02-en.jpg"/></fig>
      <p> The patients with ACS and ST-elevation presented a significant decrease in the serologic titers from the samples obtained six months after hospital admission, regarding the Cp (p=0.0001) as well as the Mp (p=0.0004). </p>
      <p>The same serologic behavior was not observed in the group without ST elevation, for Cp as well as for Mp (p=0.27 and 0.99 respectively). </p>
      <p>
        <bold>Comparison between the serologic values obtained at the start of the study</bold>
      </p>
      <p><xref ref-type="fig" rid="cht03-body3">Charts 3</xref> and <xref ref-type="fig" rid="cht04-body3">4</xref> compare the serologic differences among the different studied groups (first serologic sample). It can be observed that, in the groups that presented acute myocardial ischemia (ACS with and without ST elevation), higher serologic values were observed when compared to the groups that did not have the acute event (chronic atherosclerosis and control), regarding Cp as well as Mp, although these differences were not statistically significant.</p>
      <fig id="cht03-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gf03-en.jpg"/></fig>
      <fig id="cht04-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0439-00005-gf04-en.jpg"/></fig>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>The present study was motivated by the need to clinically evaluate the concomitant presence of <italic>Mycoplasma pneumoniae </italic>and <italic>Chlamydia pneumoniae</italic> in coronary atheromatous lesions, previously described by Higuchi et al<sup>9</sup> and cols. in necropsy findings. </p>
      <p>Agents like <italic>Chlamydia, Mycoplasma </italic>and others that cause acute respiratory infections are high-prevalence pathogens, so at the adult age, most of the population already has antibodies in serum-epidemiological assessments. Therefore, the control group individuals were not paired for age, as in the adult age, it is assumed that there is no association between the serologic values and age range. Thus, when choosing younger individuals for this group (blood donors), the possibility of non-clinically detectable CAD was also decreased. </p>
      <p>We chose the class IgG immunoglobulin because it has a mean life of 20 to 30 days and it is the antibody (Ab) that better expresses the activity of the infectious process, due to previous re-infections<sup>14</sup>. </p>
      <p><xref ref-type="fig" rid="cht01-body3">Charts 1</xref> and <xref ref-type="fig" rid="cht02-body3">2</xref> show that the patients who presented ACS with ST elevation had a significant decrease in the anti-Cp and anti-Mp Ab titers. This decrease strongly suggests that the Chlamydia and Mycoplasma present in the atherosclerotic plaque had been active, as the occurrence of simultaneous re-infection by the two agents would be very unlikely.</p>
      <p>It can be speculated that the co-infection of the atherosclerotic plaque might have been the "trigger" that activated these two agents, starting the inflammatory cascade that, in turn, would lead to the acute coronary event. </p>
      <p>In the group without ST-elevation, only a slight, non-significant decrease in the anti-Cp serologic levels was observed, with values that were practically identical in relation to the Mp. These findings suggest that, in this form of ACS, there would be an infectious reactivation of lower intensity, leading to lesser atherosclerotic plaque damage. </p>
      <p>When we compare the four groups, using the samples collected at the first phase of the study, one can observe higher serologic values in the groups that presented acute coronary event when compared to the other two groups (chronic atherosclerosis and controls, regarding the anti-Cp as well as the anti-Mp Ab). However, the differences were not statistically significant. </p>
      <p>Additionally, no significant differences were observed regarding the serologic values for Chlamydia as well as for Mycoplasma between the chronic atherosclerosis and control groups. These data suggest that the participation of the infectious process can be restricted only to the plaque destabilization mechanisms. Finally, similar results were demonstrated between the serologic values found in the control and chronic atherosclerosis groups; however, one cannot rule out the possibility (in our opinion, a remote one) that this occurred because the control group already had an ongoing atherosclerotic process. </p>
      <p>It becomes difficult to compare the results of the present study and the other serum-epidemiologic studies, as there are important methodological differences between them. The majority of these studies was retrospective,<sup>3,5, 15-17</sup> and the few prospective ones used varied Ab measurement techniques and different criteria for serologic positivity<sup>4,6,18</sup>. On the other hand, some of these studies demonstrated that a high load of pathogens, when acting simultaneously in the same individual, could exacerbate the atherosclerotic process<sup>19,20</sup>, which is in disagreement with the findings of the present study. </p>
      <p>
        <bold>Conclusions</bold>
      </p>
      <p>The present study demonstrates an association between titers of anti-Cp and anti-Mp antibodies and acute coronary disease. It also demonstrates the normalization of the titers within a six-month period, starting from the patient's clinical destabilization. </p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>This study was partially funded by FAPESP.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of doctoral submitted by Irineu Luiz Maia, from Instituto do Cora&#231;&#227;o da Faculdade de Medicina da Universidade de S&#227;o Paulo e Faculdade de Medicina de S&#227;o Jos&#233; do Rio Preto.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
